share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bassler Bonnie L

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bassler Bonnie L

再生元制药公司 | 4:持股变动声明-董事 Bassler Bonnie L
美股SEC公告 ·  01/06 21:09

Moomoo AI 已提取核心信息

On January 2, 2025, Bonnie L Bassler, a director at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, Bassler's direct ownership of Regeneron Common Stock increased to 1,548 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing. This grant appears to be part of the company's equity compensation program for directors.
On January 2, 2025, Bonnie L Bassler, a director at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, Bassler's direct ownership of Regeneron Common Stock increased to 1,548 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing. This grant appears to be part of the company's equity compensation program for directors.
2025年1月2日,再生元制药公司的董事Bonnie L Bassler被授予了166股普通股,价格为每股0美元。此次交易被报告为代码为'A'的直接收购,表明这是一次授予、奖励或其他收购。在此次交易后,Bassler在再生元的普通股直接持有量增加至1,548股。此次收购在报告日期完成,文件中未提及其他交易。该授予似乎是公司为董事提供的股权补偿计划的一部分。
2025年1月2日,再生元制药公司的董事Bonnie L Bassler被授予了166股普通股,价格为每股0美元。此次交易被报告为代码为'A'的直接收购,表明这是一次授予、奖励或其他收购。在此次交易后,Bassler在再生元的普通股直接持有量增加至1,548股。此次收购在报告日期完成,文件中未提及其他交易。该授予似乎是公司为董事提供的股权补偿计划的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息